Skip to main content

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
Cancel
×
×
Home
  • Home
Article
  • Cited by 17
  • Cited by
    Crossref Citations
    Crossref logo
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.
    Shall, Gabrielle Menosky, Megan Decker, Sarah Nethala, Priya Welchko, Ryan Leveque, Xavier Lu, Ming Sandstrom, Michael Hochgeschwender, Ute Rossignol, Julien and Dunbar, Gary 2018. Effects of Passage Number and Differentiation Protocol on the Generation of Dopaminergic Neurons from Rat Bone Marrow-Derived Mesenchymal Stem Cells. International Journal of Molecular Sciences, Vol. 19, Issue. 3, p. 720.
    Caggiu, Elisa Paulus, Kai Arru, Giannina Piredda, Rosanna Sechi, Gian Pietro and Sechi, Leonardo A. 2016. Humoral cross reactivity between α-synuclein and herpes simplex-1 epitope in Parkinson's disease, a triggering role in the disease?. Journal of Neuroimmunology, Vol. 291, Issue. , p. 110.
    Bu, Xian-Le Wang, Xin Xiang, Yang Shen, Lin-Lin Wang, Qing-Hua Liu, Yu-Hui Jiao, Shu-Sheng Wang, Ye-Ran Cao, Hong-Yuan Yi, Xu Liu, Cheng-Hui Deng, Bo Yao, Xiu-Qing Xu, Zhi-Qiang Zhou, Hua-Dong and Wang, Yan-Jiang 2015. The association between infectious burden and Parkinson's disease: A case-control study. Parkinsonism & Related Disorders, Vol. 21, Issue. 8, p. 877.
    Hack, Nawaz Jicha, Gregory A. Abell, Annalisa Dean, Dawson Vitek, Jerrold L. and Berger, Joseph R. 2012. Substantia nigra depigmentation and exposure to encephalitis lethargica. Annals of Neurology, Vol. 72, Issue. 6, p. 912.
    Benedetto, Alexandre Au, Catherine Avila, Daiana Silva Milatovic, Dejan Aschner, Michael and Ashrafi, Kaveh 2010. Extracellular Dopamine Potentiates Mn-Induced Oxidative Stress, Lifespan Reduction, and Dopaminergic Neurodegeneration in a BLI-3–Dependent Manner in Caenorhabditis elegans. PLoS Genetics, Vol. 6, Issue. 8, p. e1001084.
    Hardy, John 2006. No definitive evidence for a role for the environment in the etiology of Parkinson's Disease. Movement Disorders, Vol. 21, Issue. 10, p. 1790.
    Kanthasamy, Anumantha G. Kitazawa, Masashi Kanthasamy, Arthi and Anantharam, Vellareddy 2005. Dieldrin-Induced Neurotoxicity: Relevance to Parkinson's Disease Pathogenesis. NeuroToxicology, Vol. 26, Issue. 4, p. 701.
    Smeyne, Richard Jay and Jackson-Lewis, Vernice 2005. The MPTP model of Parkinson's disease. Molecular Brain Research, Vol. 134, Issue. 1, p. 57.
    JACKSON-LEWIS, VERNICE and SMEYNE, RICHARD JAY 2005. Animal Models of Movement Disorders. p. 149.
    Chalimoniuk, Malgorzata Stępień, A and Strosznajder, J B 2004. Pergolide Mesylate, a Dopaminergic Receptor Agonist, Applied With l-DOPA Enhances Serum Antioxidant Enzyme Activity in Parkinson Disease. Clinical Neuropharmacology, Vol. 27, Issue. 5, p. 223.
    Cook, Ruby Lu, Lu Gu, Jing Williams, Robert W and Smeyne, Richard Jay 2003. Identification of a single QTL, Mptp1, for susceptibility to MPTP-induced substantia nigra pars compacta neuron loss in mice. Molecular Brain Research, Vol. 110, Issue. 2, p. 279.
    Nelson, Dewey A and Paulson, George W 2002. Idiopathic Parkinson’s disease(s) may follow subclinical episodes of perivenous demyelination. Medical Hypotheses, Vol. 59, Issue. 6, p. 762.
    Jiang, Dongmei Jha, Nandita Boonplueang, Rapee and Andersen, Julie K. 2001. Caspase 3 inhibition attenuates hydrogen peroxide-induced DNA fragmentation but not cell death in neuronal PC12 cells. Journal of Neurochemistry, Vol. 76, Issue. 6, p. 1745.
    Smeyne, Michelle Goloubeva, Olga and Smeyne, Richard J. 2001. Strain-dependent susceptibility to MPTP and MPP+-induced Parkinsonism is determined by glia. Glia, Vol. 34, Issue. 2, p. 73.
    Delaney, Catherine L. Russell, James W. Cheng, Hsin-Lin and Feldman, Eva L. 2001. Insulin-Like Growth Factor-I and Over-Expression of Bcl-xL Prevent Glucose-Mediated Apoptosis in Schwann Cells. Journal of Neuropathology & Experimental Neurology, Vol. 60, Issue. 2, p. 147.
    Kitazawa, Masashi Anantharam, Vellareddy and Kanthasamy, Anumantha G. 2001. Dieldrin-induced oxidative stress and neurochemical changes contribute to apoptopic cell death in dopaminergic cells. Free Radical Biology and Medicine, Vol. 31, Issue. 11, p. 1473.
    Borlongan, Cesario V. Su, Tsung-Ping and Wang, Yun 2000. Treatment with delta opioid peptide enhances in vitro and in vivo survival of rat dopaminergic neurons. NeuroReport, Vol. 11, Issue. 5, p. 923.
    ×
  • Access

Etiology of Parkinson's Disease

  • A. Jon Stoessl (a1)
Abstract

Controversy over the etiology and pathogenesis of Parkinson's disease (PD) has continued for many years and while the details have changed, the uncertainty persists. Although heritability was most emphatically refuted a decade ago by many investigators, recent progress firmly indicates that genetic factors at least play a role, although probably to a variable degree from one individual to another. Evidence for a variety of other etiological factors is amassed from epidemiological studies, animal models, molecular and cellular biology. Genetic factors, infectious and immunological abnormalities, the effects of ageing, toxins (endogenous as well as exogenous) and other environmental factors may all contribute to the development of PD. Loss of nigral dopaminergic neurons may be mediated by varying combinations of oxidative free radical toxicity, impaired mitochondrial function, “weak excitotoxicity” and abnormal handling of cytoskeletal proteins, all of which may shift the balance regulating apoptotic cell death.

RÉSUMÉ

La controverse entourant l'étiologie et la pathogenèse de la maladie de Parkinson (MP) dure depuis plusieurs années et, bien que les détails ont changé, l'incertitude persiste. Bien que l'héritabilité de la maladie ait été réfutée avec emphase par plusieurs investigateurs il y a une dizaine d'années, des progrès récents indiquent clairement que des facteurs génétiques sont en cause, probablement à des degrés variables d'un individu à l'autre. Des données sur une variété d'autres facteurs étiologiques, provenant d'études épidémiologiques, de modèles animaux, de la biologie moléculaire et cellulaire, s'accumulent. Les facteurs génétiques, anomalies infectieuses et immunologiques, les effets du vieillissement, les toxines (endogènes et exogènes) et les autres facteurs environnementaux peuvent contribuer au développement de la MP. La perte de neurones dopaminergiques dans la substance noire peut être médiée par différentes combinaisons d'effets toxiques oxydatifs dus à des radicaux libres, une fonction mitochondriale altérée, une “faible excitotoxicité” et un métabolisme anormal des protéines du cytosquelette, qui peuvent tous déséquilibrer la régulation de la mort cellulaire par apoptose.

    •
      • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Etiology of Parkinson's Disease
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Etiology of Parkinson's Disease
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Etiology of Parkinson's Disease
      Available formats
      ×
Copyright
COPYRIGHT: © The Canadian Journal of Neurological 1999
References
Hide All
1. Rajput, AH. Frequency and cause of Parkinson’s disease. Can J Neurol Sci 1992; 19 (Suppl. 1): 103–107.
2. Rajput, AH, Rozdilsky, B, Rajput, A. Accuracy of clinical diagnosis in Parkinsonism-a prospective study. Can J Neurol Sci 1991; 18: 275–278.
3. Semchuk, KM, Love, EJ. Effects of agricultural work and other prox-derived case-control data on Parkinson’s disease risk estimates. Am J Epidemiol 1995; 141: 747–754.
4. Ward, CD, Duvoisin, RC, Ince, SE, Nutt, JD, Eldridge, R, Calne, DB. Parkinson’s disease in 65 pairs of twins and in a set of quadruplets. Neurology 1983; 33: 815–824.
5. Vieregge, P, Schiffke, KA, Friedrich, HJ, Muller, B, Ludin, HP. Parkinson’s disease in twins. Neurology 1992; 42: 1453–1461.
6. Burn, DJ, Mark, MH, Playford, ED, et al. Parkinson’s disease in twins studied with 18F-dopa and positron emission tomography. Neurology 1992; 42: 1894–1900.
6a. Tanner, CM, Ottman, R, Goldman, SM, Ellenberg, J, Chan, P, Mayeux, R, Langston, JW. Parkinson disease in twins: an etiologic study. JAMA 1999; 281: 341–346.
7. Payami, H, Larsen, K, Bernard, S, Nutt, J. Increased risk of Parkinson’sdisease in parents and siblings of patients. Ann Neurol 1994; 36: 659–661.
8. Golbe, LI, Di Iorio, G, Bonavita, , Miller, DC, Duvoisin, RC. A large kindred with autosomal dominant Parkinson’s disease. Ann Neurol 1990; 27: 276–282.
9. Polymeropoulos, MH, Lavedan, C, Leroy, E, et al. Mutation in the asynuclein gene identified in families with Parkinson’s disease. Science 1997; 276: 2045–2047.
10. Kruger, R, Kuhn, W, Muller, T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nature Genetics 1998; 18: 106–108.
11. Scott, WK, Staijich, JM, Yamaoka, LH, et al. Genetic complexity and Parkinson’s disease. Science 1997; 277: 387–388.
12. Gasser, T, Muller-Myhsok, B, Wszolek, ZK, et al. Genetic complexity and Parkinson’s disease. Science 1997; 277: 388–389.
13. Chan, P, Jiang, X, Forno, LS, Di Monte, DA, Tanner, CM, Langston, JW. Absence of mutations in the coding region of the alpha-synu-clein gene in pathologically proven Parkinson’s disease. Neurology 1998; 50: 1136–1137.
14. Gasser, T, Muller-Myhsok, B, Wszolek, ZK, et al. A susceptibility locus for Parkinson’s disease maps to chromosome 2p13. Nature Genetics 1998; 18: 262–265.
14a. Swerdlow, RH, Parks, JK, Miller, SW et al. Origin and functional consequences of the complex I defect in Parkinson’s disease. Ann. Neurol. 1996; 40: 663–671.
15. Shimoda-Matsubayashi, S, Hattori, T, Matsumine, H, et al. Mn SOD activity and protein in a patient with chromosome 6-linked autosomal recessive parkinsonism in comparison with Parkinson’s disease and control. Neurology 1997; 49: 1257–1262.
16. Kitada, T, Asakawa, S, Hattori, N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392: 605–608.
16a. Leroy, E, Boyer, R, Auburger, G et al. The ubiquitin pathway in Parkinson’s disease. Nature 1998; 395: 451–452.
17. Kurth, JH, Kurth, MC, Poduslo, SE, Schwankhaus, JD. Association of a monoamine oxidase B allele with Parkinson’s disease. Ann Neurol 1993; 33: 368–372.
18. Parboosingh, JS, Rousseau, M, Rogan, F, et al. Absence of mutations in superoxide dismutase and catalase genes in patients with Parkinson’s disease. Arch Neurol 1995; 52: 1160–1163.
19. Gasser, T, Wszolek, ZK, Trofatter, J, et al. Genetic linkage studies in autosomal dominant parkinsonism: evaluation of seven candidate genes. Ann Neurol 1994; 36: 387–396.
20. Schoenberg, BS, Anderson, DW, Haerer, AF. Prevalence of Parkinson’s disease in the biracial population of Copiah County, Mississippi. Neurology 1985; 35: 841–845.
21. Jendroska, K, Olasode, BJ, Daniel, SE, et al. Incidental Lewy body disease in black Africans. Lancet 1994; 344: 882–883.
22. Wang, SJ, Fuh, JL, Teng, EL, et al. A door-to-door survey of Parkinson’s disease in a Chinese population in Kinmen. Arch Neurol 1996; 53: 66–71.
23. Zhang, Z-X, Roman, GC. Worldwide occurrence of Parkinson’s disease: an updated review. Neuroepidemiol 1993; 12: 195–208.
24. Calne, S, Schoenberg, B, Martin, W, Uitti, RJ, Spencer, P, Calne, DB. Familial Parkinson’s disease: possible role of environmental factors. Can J Neurol Sci 1987; 14: 303–305.
25. Rajput, AH, Uitti, RJ, Stern, W, et al. Geography, drinking water chemistry, pesticides and herbicides and the etiology of Parkinson’s disease. Can J Neurol Sci 1987; 14: 414–418.
26. Butterfield, PG, Valanis, BG, Spencer, PS, Lindeman, CA, Nutt, JG. Environmental antecedents of young-onset Parkinson’s disease. Neurology 1993; 43: 1150–1158.
27. Hubble, JP, Cao, T, Hassanein, RES, Neuberger, JS, Koller, WC. Risk factors for Parkinson’s disease. Neurology 1993; 43: 1693–1697.
28. Semchuk, KM, Love, EJ, Lee, RG. Parkinson’s disease: a test of the multifactorial etiologic hypothesis. Neurology 1993; 43: 1173–1180.
29. Stern, M, Dulaney, E, Gruber, SB, et al. The epidemiology of Parkinson’s disease: a case-control study of young-onset and old-onset patients. Arch Neurol 1991; 48: 903–907.
30. Fleming, L, Mann, JB, Bean, J, Briggle, T, Sanchez-Ramos, JR. Parkinson’s disease and brain levels of organochlorine pesticides. Ann Neurol 1994; 36: 100–103.
31. Wang, W-z, Fang, X-h, Cheng, X-m, Jiang, D-h, Lin, Z-j. A case-control study on the environmental risk factors of Parkinson’s disease in Tianjin, China. Neuroepidemiology 1993; 12: 209–218.
32. Chaturvedi, S, Ostbye, T, Stoessl, AJ, Merskey, H, Hachinski, V. Environmental exposures in elderly Canadians with Parkinson’s disease. Can J Neurol Sci 1995; 22: 232–234.
33. Godwin-Austen, RG, Leigh, PN, Marmot, MG, Stern, GM. Smoking and Parkinson’s disease. J Neurol Neurosurg Psychiatry 1982; 45: 577–581.
34. Mayeux, R, Tang, MX, Marder, K, Cote, LJ, Stern, Y. Smoking and Parkinson’s disease. Mov Disord 1994; 9: 207–212.
35. Morens, DM, Grandinetti, A, Reed, D, White, LR, Ross, GW. Cigarette smoking and protection from Parkinson’s disease: false association or etiologic clue? Neurology 1995; 45: 1041–1051.
36. Riggs, JE. Cigarette smoking and Parkinson disease: the illusion of a neuroprotective effect. Clin Neuropharm 1992; 15: 88–99.
37. Grandinetti, A, Morens, DM, Reed, D, MacEachern, D. Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson’s disease. Am J Epidemiol 1994; 139: 1129–1138.
38. Williams, DB, Annegers, JF, Kokmen, E, O’Brien, PC, Kurland, LT. Brain injury and neurologic sequelae: a cohort study of dementia, parkinsonism, and amyotrophic lateral sclerosis. Neurology 1991; 41: 1554–1557.
39. Lin, SK, Lu, CS, Vingerhoets, FJG, et al. Isolated involvement of substantia nigra in acute transient Parkinsonism: MRI and PET observations. Parkinsonism Rel Disord 1995; 1: 67–73.
40. Takahashi, M, Yamada, T, Nakajima, S, Nakajima, K, Yamamoto, T, Okada, H. The substantia nigra is a major target for neurovirulent influenza A virus. J Exp Med 1995; 181: 2161–2169.
41. McGeer, PL, Itagaki, S, Boyes, BE, McGeer, EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease of brains. Neurology 1988; 38: 1285–1291.
42. Defazio, G, Daltoso, R, Benvegnu, D, Minozzi, MC, Cananzi, AR, Leon, A. Parkinsonian serum carries complement-dependent toxicity for rat mesencephalic dopaminergic neurons in culture. Brain Res 1994; 633: 206–212.
43. McGeer, PL, McGeer, EG, Suzuki, JS. Aging and extrapyramidal function. Arch Neurol 1977; 34: 33–35.
44. Kish, SJ, Shannak, K, Rajput, A, Deck, JHN, Hornykiewicz, O. Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson’s disease. J Neurochem 1992; 58: 642–648.
45. Lee, CS, Schulzer, M, Mak, EK, et al. Clinical observations on the rate of progression of idiopathic parkinsonism. Brain 1994; 117: 501–507.
46. Calne, DB. Is idiopathic parkinsonism the consequence of an event or a process? Neurology 1994; 44: 4–10.
47. Schulzer, M, Lee, CS, Mak, EK, Vingerhoets, FJG, Calne, DB. A mathematical model of pathogenesis in idiopathic parkinsonism. Brain 1994; 117: 509–516.
48. Hallman, H, Lange, J, Olson, L, Stromberg, I, Jonsson, G. Neurochemical and histochemical characterization of neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurones in the mouse. J Neurochem 1985; 44: 117–127.
49. Willis, GL, Donnan, GA. Histochemical, biochemical and behavioural consequences of MPTP treatment in C-57 black mice. Brain Res 1987; 402: 269–274.
50. Kalaria, RN, Mitchell, MJ, Harik, SI. Correlation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity with blood-brain barrier monoamine oxidase activity. Proc Natl Acad Sci USA 1987; 84: 3521–3525.
51. Giovanni, A, Sonsalla, PK, Heikkila, RE. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahy-dropyridine. 2. Central administration of 1-methyl-4-phenylpyri-dinium. J Pharmacol Exp Therap 1994; 270: 1008–1014.
52. Heikkila, RE, Nicklas, WJ, Duvoisin, RC. Dopaminergic toxicity after the stereotaxic adminstration of the 1-methyl-4-phenylpyridinium ion (MPP+) to rats. Neurosci Lett 1985; 59: 135–140.
53. Bradbury, AJ, Costall, B, Domeny, AM, et al. 1-methyl-4-phenylpyri-dine is neurotoxic to the nigrostriatal dopamine pathway. Nature 1986; 319: 56–57.
54. Gerlach, M, Riederer, P, Przuntek, H, Youdim, MBH. MPTP mechanisms of neurotoxicity and their implications for Parkinson’s disease. Eur J Pharmacol 1991; 208: 273–286.
55. McNaught, KS, Thull, U, Carrupt, PA, et al. Inhibition of complex I by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Biochem Pharmacol 1995; 50: 1903–1911.
56. Maruyama, W, Naoi, M, Kasamatsu, T, et al. An endogenous dopaminergic neurotoxin, N-methyl-(R)-salsolinol, induces DNA damage in human dopaminergic neuroblastoma SH-SY5Y cells. J Neurochem 1997; 69: 322–329.
57. Turski, L, Bressler, K, Rettig, K-J, Loschmann, P-A, Wachtel, H. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 1991; 349: 414–418.
58. Sawada, H, Shimohama, S, Tamura, Y, Kawamura, T, Akaike, A, Kimura, J. Methylphenylpyridinium ion (MPP+) enhances gluta-mate-induced cytotoxicity against dopaminergic neurons in cultured rat mesencephalon. J Neurosci Res 1996; 43: 55–62.
59. Beal, MF. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 1995; 38: 357–366.
60. Piallat, B, Benazzouz, A, Benabid, AL. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after stri-atal 6-OHDA injection: behavioural and immunohistochemical studies. Eur J Neurosci 1996; 8: 1408–1414.
61. Uitti, RJ, Rajput, AH, Ahlskog, JE, et al. Amantadine treatment is an independent predictor of improved survival in Parkinson’s disease. Neurology 1996; 46: 1551–1556.
62. Sian, J, Dexter, DT, Lees, AJ, et al. Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994; 36: 348–355.
63. Dexter, DT, Sian, J, Rose, S, et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 1994; 35: 38–44.
64. Sian, J, Dexter, DT, Lees, AJ, Daniel, S, Jenner, P, Marsden, CD. Glutathione-related enzymes in brain in Parkinson’s disease. Ann Neurol 1994; 36: 356–361.
65. Olanow, CW, Cohen, G, Perl, DP, Marsden, CD Role of iron and oxidant stress in the normal and parkinsonian brain. Ann Neurol 1992; 32: S1-S145.(Abstract)
66. Youdim, MBH, Ben-Shachar, D, Riederer, P. The possible role of iron in the etiopathology of Parkinson’s disease. Mov Disord 1993; 8: 1–12.
67. Rosen, DR, Siddique, T, Patterson, D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59–62.
68. Gurney, ME, Pu, H, Chiu, AY, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994; 264: 1772–1775.
69. Beckman, JS, Chen, J, Crow, JP, Ye, YZ. Reactions of nitric oxide, superoxide and peroxynitrite with superoxide dismutase in neurodegeneration. Prog Brain Res 1994; 103: 371–380.
69a. Dexter, DT, Carayon, A, Javoy-Agid, F, Agid, Y, Wells, FR, Daniel, SE, Lees, AJ, Jenner, P, Marsden, CD. Alterations in the levels of iron, ferritin and other trace metals in Parkinson’s disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991; 114: 1953–1975.
69b. Mann, VM, Cooper, JM, Daniel, SE, Srai, K, Jenner, P, Marsden, CD, Schapira, AH. Complex I, iron, and ferritin in Parkinson’s disease substantia nigra. Ann. Neurol. 1994; 36: 876–881.
70. Toffa, S, Kunikowska, GM, Zeng, BY, Jenner, P, Marsden, CD. Glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration. J Neural Transm 1997; 104: 67–75.
71. Wullner, U, Loschmann, PA, Schulz, JB, et al. Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurons. NeuroReport 1996; 7: 921–923.
72. Li, YH, Maher, P, Schubert, D. A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion. Neuron 1997; 19: 453–463.
73. Dexter, DT, Holley, AE, Flitter, WD, et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord 1994; 9: 92–97.
74. Sanchez-Ramos, JR, Overvik, E, Ames, BN. A marker of oxyradical-mediated DNA damage (8-hydroxy-2’-deoxyguanosine) is increased in nigrostriatum of Parkinson’s disease brain. Neurodegeneration 1994; 3: 197–204.
75. DiMauro, S. Mitochondrial involvement in Parkinson’s disease: the controversy continues. Neurology 1993; 43: 2170–2172.
76. Schapira, AHV. Evidence for mitochondrial dysfunction in Parkinson’s disease – a critical reappraisal. Mov Disord 1994; 9: 125–138.
77. Przedborski, S, Kostic, V, Jackson-Lewis, V, et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neuro-toxicity. J Neurosci 1992; 12: 1658–1667.
78. Ferrante, RJ, Schulz, JB, Kowall, NW, Beall, MF. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res 1997; 753: 157–162.
79. Calne, DB. The free radical hypothesis in idiopathic parkinsonism: evidence against it. Ann Neurol 1992; 32: 799–803.
80. Fahn, S, Cohen, G. The oxidant stress hypothesis in Parkinson’s disease: evidence supporting it. Ann Neurol 1992; 32: 804–812.
81. Jenner, P, Schapira, AHV, Marsden, CD. New insights into the cause of Parkinson’s disease. Neurology 1992; 42: 2241–2250.
82. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP subjects not requiring levodopa. Ann Neurol 1996; 39: 29–36.
83. Dexter, DT, Brooks, DJ, Harding, AE, et al. Nigrostriatal function in vitamin E deficiency: clinical, experimental, and positron emission tomographic studies. Ann Neurol 1995; 35: 298–303.
84. Mena, MA, Davila, V, Sulzer, D. Neurotrophic effects of L-dopa in postnatal midbrain dopamine/cortical astrocyte cocultures. J Neurochem 1997; 69: 1398–1408.
85. Agid, Y. Levodopa. Is toxicity a myth? Neurology 1998; 50: 858–863.
86. Murer, MG, Dziewczapolski, G, Menalled, LB, et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 1998; 43: 561–575.
87. Rajput, AH, Uitti, RJ, Rajput, A, Offord, KP. Timely levodopa (LD) administration prolongs survival in Parkinson’s disease. Parkinsonism Rel Disord 1997; 3: 159–165.
88. Przuntek, H, Welzel, D, Blumner, E, et al. Bromocriptine lessens the incidence of mortality in L-Dopa- treated parkinsonian patients: PRADO-study discontinued. Eur J Clin Pharmacol 1992; 43: 357–363.
89. Hyman, C, Hofer, M, Barde, YA, et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1991; 350: 230–232.
90. Lin, L-FH, Doherty, DH, Lile, JD, Bektesh, S, Collins, F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopamin-ergic neurons. Science 1993; 260: 1130–1132.
91. Tomac, A, Widenfalk, J, Lin, L-FH, et al. Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. Proc Natl Acad Sci USA 1995; 92: 8274–8278.
92. Tomac, A, Lindquist, E, Lin, L-FH, et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995; 373: 335–339.
93. Beck, KD, Valverde, J, Alexi, T, et al. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 1995; 373: 339–341.
94. Lindner, MD, Winn, SR, Baetge, EE, et al. Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms. Exp Neurol 1995; 132: 62–76.
95. Choi-Lundberg, DL, Lin, Q, Chang, YN, et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 1997; 275: 838–841.
96. Steiner, JP, Hamilton, GS, Ross, DT, et al. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. Proc Natl Acad Sci USA 1997; 94: 2019–2024.
97. Wang, MZ, Jin, P, Bumcrot, DA, et al. Induction of dopaminergic neuron phenotype in the midbrain by Sonic hedgehog protein. Nature Medicine 1995; 1: 1184–1188.
98. Horger, BA, Nishimura, MC, Armanini, MP, et al. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J Neurosci 1998; 18: 4929–4937.
99. Zetterstrom, RH, Solomin, L, Jansson, L, Hoffer, BJ, Olson, L, Perlmann, T. Dopamine neuron agenesis in Nurr1-deficient mice. Science 1997; 276: 248–250.
100. Tooyama, I, Kawamata, T, Walker, D, et al. Loss of basic fibroblast growth factor in substantia nigra neurons in Parkinson’s disease. Neurology 1993; 43: 372–376.
101. Gagliardini, V, Fernandez, P-A, Lee, RKK, et al. Prevention of vertebrate neuronal death by the crmA gene. Science 1994; 263: 826–828.
102. Bump, NJ, Hackett, M, Hugunin, M, et al. Inhibition of ICE family proteases by baculovirus antiapoptotic protein p35. Science 1995; 269: 1885–1888.
103. Milligan, CE, Prevette, D, Yaginuma, H, et al. Peptide inhibitors of the ICE protease family arrest programmed cell death of motoneurons in vivo and in vitro. Neuron 1995; 15: 385–393.
104. Barinaga, M. Death by dozens of cuts. Science 1998; 280: 32–34.
105. Mochizuki, H, Goto, K, Mori, H, Mizuno, Y. Histochemical detection of apoptosis in Parkinson’s disease. J Neurol Sci 1996; 137: 120–123.
106. Tompkins, MM, Basgall, EJ, Zamrini, E, Hill, WD. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. Am J Pathol 1997; 150: 119–131.
107. Anglade, P, Vyas, S, Javoy-Agid, F, et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson’s disease. Histol Histopathol 1997; 12: 25–31.
108. Kosel, S, Egensperger, R, vonEitzen, U, Mehraein, P, Graeber, MB. On the question of apoptosis in the parkinsonian substantia nigra. Acta Neuropathol 1998; 93: 105–108.
109. Mogi, M, Harada, M, Kondo, T, et al. Bcl-2 protein is increased in the brain from parkinsonian patients. Neurosci Lett 1996; 215: 137–139.
110. Troy, CM, Shelanski, ML. Down-regulation of copper/zinc superoxide dismutase causes apoptotic death in PC12 neuronal cells. Proc Natl Acad Sci USA 1994; 91: 6384–6387.
111. Hartley, A, Stone, JM, Heron, C, Cooper, JM, Schapira, AHV. Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson’s disease. J Neurochem 1994; 63: 1987–1990.
112. Ziv, I, Melamed, E, Nardi, N, et al. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons – a possible novel pathogenetic mechanism in Parkinson’s disease. Neurosci Lett 1994; 170: 136–140.
113. Tatton, NA, Kish, SJ. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahy-dropyridine-treated mice using terminal deoxynucleotidyl trans-ferase labelling and acridine orange staining. Neuroscience 1997; 77: 1037–1048.
114. Bonfoco, E, Krainc, D, Ankarcrona, M, Nicotera, P, Lipton, SA. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci USA 1995; 92: 7162–7166.
115. Estevez, AG, Radi, R, Barbeito, L, Shin, JT, Thompson, JA, Beckman, JS. Peroxynitrite-induced cytotoxicity in PC12 cells: evidence for an apoptotic mechanism differentially modulated by neurotroph-ic factors. J Neurochem 1995; 65: 1543–1550.
116. Hunot, S, Brugg, B, Ricard, D, et al. Nuclear translocation of NF-KB is increased in dopaminergic neurons of patients with Parkinson disease. Proc Natl Acad Sci USA 1997; 94: 7531–7536.
117. Patil, N, Cox, DR, Bhat, D, Faham, M, Myers, RM, Peterson, AS. A potassium channel mutation in weaver mice implicates membrane excitability in granule cell differentiation. Nature Genetics 1995; 11: 126–129.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Canadian Journal of Neurological Sciences
  • ISSN: 0317-1671
  • EISSN: 2057-0155
  • URL: /core/journals/canadian-journal-of-neurological-sciences
Please enter your name
Please enter a valid email address
Who would you like to send this to? *

CAPTCHA *

Skip to the audio challenge
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 142 *
Loading metrics...

Abstract views

Total abstract views: 404 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 12th June 2018. This data will be updated every 24 hours.

Cancel
Confirm
×